May, 2025
May 2025
M T W T F S S
 1234
567891011
12131415161718
19202122232425
262728293031  
Amol Akhade: CDK4/6 Rechallenge Trials – What Works and What Doesn’t?
May 7, 2025, 07:31

Amol Akhade: CDK4/6 Rechallenge Trials – What Works and What Doesn’t?

Amol Akhade, Consultant Medical Oncologist Hemato-Oncologist at Suyog Cancer Clinics, shared on LinkedIn:

“CDK4/6 Rechallenge Trials: What Works and What Doesn’t?

published in JCO – The PALMIRA Trial brings clarity!

PALMIRA Trial (2025, JCO)

Rechallenge with palbociclib + new ET vs. ET alone

Result: No significant PFS benefit
PFS: 4.9 vs. 3.6 months
HR: 0.84 | p = 0.149
Conclusion: Same-drug rechallenge fails

Switch Strategy Trials Deliver

MAINTAIN Trial

Switched to ribociclib
PFS: 5.3 vs. 2.8 months
HR: 0.57 | p = 0.006

postMONARCH Trial

Switched to abemaciclib
PFS: 6.0 vs. 5.3 months
HR: 0.73 | p = 0.02

Switching CDK4/6 inhibitors = Real benefit

ESR1 Mutations Matter
Post-CDK4/6i ESR1 mutation rate: 30–47%
ESR1 mutations drive AI resistance
Oral SERDs (e.g., elacestrant) are effective in this population

Key Takeaways

  • Palbociclib rechallenge ≠ clinical benefit
  • Switching to ribo or abema = better PFS
  • Precision matters: molecular profiling is the future
  • Practice-changing evidence is here

Let’s move from one-size-fits-all to personalized CDK4/6i strategy in HR+ MBC!”

Amol Akhade

Amol Akhade reviewed CDK4/6 Rechallenge Trials.

He concluded that rechallenging with palbociclib did not yield significant benefit, while switching to ribociclib or abemaciclib showed improved outcomes. He emphasized the role of ESR1 mutations and the importance of molecular profiling in HR+ metastatic breast cancer.

More posts featuring Amol Akhade on OncoDaily.